Company Filing History:
Years Active: 2018-2020
Title: Oleksandr Brener: Innovator in Amyloid Research
Introduction
Oleksandr Brener is a notable inventor based in Duesseldorf, Germany. He has made significant contributions to the field of amyloid research, particularly in the context of Alzheimer's disease. With a total of 3 patents to his name, Brener's work focuses on the quantitative characterization of substances that bind to amyloid-beta conformers.
Latest Patents
Brener's latest patents include a method for the quantitative characterization of substances with regard to their properties of binding to amyloid-beta (Aβ) conformers. This method involves fractionating a sample that includes various Aβ conformers, immobilizing a biotinylated Aβ conformer on a substrate, and deriving the binding behavior of a quality control probe from the measurement signal. Another significant patent involves cyclic, amyloid beta-binding peptides, which are designed to treat Alzheimer's disease. These peptides contain amino acid sequences in a cyclized form, showcasing Brener's innovative approach to medical applications.
Career Highlights
Brener is associated with Forschungszentrum Juelich GmbH, where he continues to advance his research in amyloid-related studies. His work has garnered attention for its potential impact on understanding and treating neurodegenerative diseases.
Collaborations
Brener collaborates with esteemed colleagues such as Dieter Willbold and Luitgard Nagel-Steger, contributing to a dynamic research environment focused on amyloid research.
Conclusion
Oleksandr Brener's innovative contributions to amyloid research and his patents reflect his commitment to advancing medical science. His work holds promise for future treatments of Alzheimer's disease and enhances our understanding of amyloid-beta interactions.